ledipasvir/sofosbuvir / Generic mfg.  >>  Phase 4
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ledipasvir/sofosbuvir / Generic mfg.
2015-003024-31: Protecting immune responses in patients treated with the new DAA anti hepatitis C alone or in combination with previously used medications (interferon and ribavirin) Risposte immunitarie proteggenti in pazienti trattati con i nuovi farmaci anti epatite C (nuovi DAA) da soli o in associazione con i farmaci precedentemente utilizzati (interferone e ribavirina)

Not yet recruiting
4
30
Europe
PEGINTERFERONE ALFA-2A, RIBAVIRINA, SOFOSBUVIR, LEDIPASVIR+SOFOSBUVIR, N.A., Solution for injection, Capsule, hard, Film-coated tablet, PEGASYS - 180MCG-SOLUZ. INIETTABILE-USO SOTTOCUT.-PENNA PRERIEMPITA-0.5 ML (360MCG/ML) 1 PENNA PRERIEMPITA, REBETOL - 200 MG 84 CAPSULE RIGIDE IN BLISTER, SOVALDI - 400 MG - COMPRESSA RIVESTITA CON FILM - FLACONE (HDPE) - 28 COMPRESSE, HARVONI - 90 MG/400 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - FLACONE (HDPE) - 28 COMPRESSE RIVESTITE CON FILM
AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA, GILEAD SCIENCES SRL
CHRONIC HEPATITIS C EPATITE C CRONICA, CHRONIC HEPATITIS C EPATITE C CRONICA, Diseases [C] - Virus Diseases [C02]
 
 
ChiCTR-OPC-16008158: Safety and efficacy of sofosbuvir plus ledipasvir for Chinese hepatitis C patients

Recruiting
4
100
 
sofosbuvir, ledipasvir and ribavirin ;sofosbuvir, ledipasvir and ribavirin ;sofosbuvir, ledipasvir
The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Key Scientific Research Project of Henan Higher Education Institutions of China (No. 15A320083)
Chronic hepatitis C
 
 
NCT03402165: Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C

Recruiting
4
1200
RoW
Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir, Sofaldy, Harvony
Sherief Abd-Elsalam
Hepatitis C
12/22
12/22
CHROME, NCT03823911: Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

Completed
4
87
US
Elbasvir / Grazoprevir Oral Tablet [Zepatier], Sofosbuvir/Ledipasvir, Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir/Voxilaprevir, Cardiac MRI
University of Maryland, Baltimore, National Institutes of Health (NIH), Merck Sharp & Dohme LLC
Cardiovascular Diseases, Hepatitis C, Hiv
12/22
12/22

Download Options